CA
SPRY icon

Clearstead Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Clearstead Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42 Buy
+5
New +$43 ﹤0.01% 3506

Other funds holding SPRY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
PCML
Pavaki Capital Management LLC Pueblo, Colorado $287M AUM
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return

Clearstead Advisors's SPRY Position: Q2 2026 in Review

Clearstead Advisors opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 5 shares worth $42. The stake represents ﹤0.01% of the portfolio and ranks #3506 among its holdings.

71 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Clearstead Advisors held 5 shares of ARS Pharmaceuticals worth $42 as of Q2 2026.
  • ARS Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3506 holding.
  • 71 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.